A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Rapamycin|DRUG: Trastuzumab
Sponsor: Yale University
Collaborators: Genentech, Inc.